遗传修饰全长人呼吸道合胞病毒preF蛋白疫苗的研制
研究针对人呼吸道合胞病毒(hRSV)疫苗中preF外域连接外源三聚体基序可能引发免疫学并发症的问题,设计修饰的全长preF-TMCT蛋白以模拟天然F蛋白结构。筛选出表达量高、抗原性强且稳定性好的候选构建体,其中先导构建体BR40在Balb/c小鼠中诱导出强免疫原性和交叉反应中和抗体。
要点
- 全长preF-TMCT抗原模拟天然F蛋白结构,旨在避免外源三聚体基序带来的免疫学并发症。
- 先导构建体BR40在Balb/c小鼠中显示强免疫原性并诱导交叉反应中和抗体。
- 全长preF-TMCT抗原的近天然结构可能有助于治疗性单克隆抗体及其他生物药开发。
核心结论
- 修饰的全长preF-TMCT蛋白可模拟天然F蛋白结构,先导构建体BR40在Balb/c小鼠中诱导强免疫原性和交叉反应中和抗体,为hRSV疫苗开发提供新思路。
研究设计与样本
- 研究构建并表征一组preF构建体,筛选出两个表达量高、抗原性强且稳定性好的候选,并在Balb/c小鼠中进行免疫原性评价。
主要发现
- 两个候选构建体具有理想的表达水平、高抗原性和良好稳定性。
- Balb/c小鼠免疫证实这些抗原具有强免疫原性并有效诱导交叉反应中和抗体,尤其是先导构建体BR40。
关键数值与推荐
- 先导构建体BR40在Balb/c小鼠中诱导强免疫原性和交叉反应中和抗体。
临床怎么用
- 全长preF-TMCT抗原的近天然结构使其可用于生产针对hRSV感染的治疗性单克隆抗体和其他生物药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human Respiratory Syncytial Virus (hRSV) is a major cause of acute lower respiratory tract infections (ALRTI) in infants, the elderly, and immunocompromised individuals. The recent approval of recombinant protein-based hRSV vaccines represents significant progress in combating hRSV. However, these vaccines utilized optimized preF ectodomain attached with an exogenous trimeric motif, which may induce immunological complications. Our research addresses these concerns by employing modified "full-length" preF proteins, preF-TMCT, designed to mimic the natural F protein structure and avoid potential immunological complications. We characterized a group of preF constructs and identified two candidates that exhibited desirable expression levels, high antigenicity and good stability. Immunization of Balb/c mice confirmed the robust immunogenicity and effective in induction of cross-reactive neutralizing antibodies of these antigens, particularly the lead-construct BR40. This investigation aims to contribute new insights to hRSV vaccine development. The near-native structure of the "full-length" preF-TMCT antigen also makes it valuable for producing therapeutic monoclonal antibodies (mAbs) and other biopharmaceuticals against hRSV infection.
引用
- Lao G, Feng J, Wu L, et al. Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine. Vaccine. 2025. PMID: 39874917. doi:10.1016/j.vaccine.2025.126799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。